Torsten Hoffmann's Biography

Torsten Hoffmann, Senior Vice President Drug Discovery, Hesperos

Since more than 20 years in pharmaceutical R&D. Inventor of anti-emetic medicine Netupitant, FDA approved as Akynzeo in 2014, and since 2015 recommended by the National Comprehensive Cancer Network for preferred use. At Roche, created new R&D department and delivered later 52 new lead series into lead optimization, 32 small molecules into regulatory Tox studies, and more than 25 NCEs into clinical studies over 8 years. Over past 6 years in leading roles and as Scientific Advisory Board member in the European biotechnology industry, successfully prioritized and advanced strong R&D portfolios, and implemented novel approaches to encourage and enable innovation. Authored more than 95 publications, patent applications and published conference reports.